MUSTANG BIO, INC. (MBIO) research
MUSTANG BIO, INC.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.47
- As of
MUSTANG BIO, INC. (MBIO): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-05.
As of . Source: SEC EDGAR filings for MBIO. Method and limitations.
Share the MBIO intelligence card
See the full MBIO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for MBIO on one page. Preview it with sample data, then open it live with a free account.
Preview the MBIO dossierActive signals for MBIO
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 58% of MBIO (2026Q1)
- mediumEARNINGS_MISS
Q3-2023: Missed consensus by 7.7% - EPS $-70 vs $-65.025 estimate
- mediumEARNINGS_BEAT
Q4-2023: Beat consensus by 36.6% - EPS $-43 vs $-67.83 estimate
- mediumEARNINGS_BEAT
Q3-2024: Beat consensus by 69.8% - EPS $-2 vs $-6.63 estimate
- mediumEARNINGS_MISS
Q4-2024: Missed consensus by 365.1% - EPS $-37.95 vs $-8.16 estimate
FREE, NO ACCOUNT
Every signal on MBIO, as it fires
You are seeing 5 of 9 signals recorded on MBIO since 2026-06-02.
The five above landed across 2 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in MBIO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 62818Q302 · 2026Q2 | $42K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, MBIO
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-KSEC EDGAR ↗
MBIO against its peers
MBIO's return on equity of -20.2% ranks in the 97th percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-04-30.
| Metric | MBIO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 391743 | n/a | 15 |
| Gross margin | n/a | 80.6% | n/a | 9 |
| Operating margin | n/a | -2190.0% | n/a | 13 |
| Net margin | n/a | -2419.9% | n/a | 13 |
| Return on equity | -20.2% | -205.8% | 97 | 14 |
Peers (20): GLMD, CVKD, ERNA, ADTX, AAGH, APVO, REVB, APTOF, SXTP, JUNS, PMCB, GRI, BRTX, GOVX, JAGX, EMMA, CANF, ONCO, VIVS, HCWB. Left out: ELAB (no annual filing), BVAXF (no annual filing), MLEC (period gap), ADXN (period gap), XRTX (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (MBIO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more MBIO signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to MBIOand get the insider, 13F, options, and confluence read in one view.